英语翻译

The clinical and therapeutic implications of mTOR are widespread and continue to expand.Abnormal mTOR activity, leading to excessive cellular growth and proliferation, has been implicated in the pathophysiology of numerous human cancers, including both sporadic,isolated tumors of specific organs and multiorgan, genetic tumor syndromes (Guertin and Sabatini, 2007). In many of these cases, specific mutations of some component of the mTOR signaling pathway have been documented, resulting in hyperactivation of mTOR or its downstream effectors. Besides cancer, dysregulation of mTOR has also been implicated in a number of other diseases, involving metabolic or environmental derangements, such as diabetes, obesity, cardiovascular disease, and neurodegenerative disorders (Tsang et al.,2007). From a translational standpoint, the potential role of mTOR in the pathophysiology ofthese various disorders has immediate therapeutic implications, as a number of clinically available drugs exist that inhibit mTOR, including the prototype, rapamycin. Thus, rapamycin and other mTOR inhibitors are already being tested in clinical trials for various cancers and other diseases (Dancey, 2006; Tsang et al., 2007).

Overall, mTOR appears to serve as a master switch responding to different physiological
and pathological stimuli to maintain homeostasis by regulating cellular growth,
proliferation, and survival. mTOR is increasingly recognized to be involved in a large
spectrum of physiological functions under normal conditions and to be dysregulated in a diverse group of diseases. mTOR inhibitors, such as rapamycin, are being considered or are already in clinical trials for a number of these diseases. Based on the physiological and pathophysiological properties of mTOR, it is reasonable to hypothesize that mTOR
signaling could be involved in mechanisms of epileptogenesis. In the remainder of this
review, evidence for the role of mTOR in epileptogenesis and the potential utility of mTOR inhibitors as anti-epileptogenic agents will be analyzed in different types of epilepsies, starting with the genetic epilepsy, Tuberous Sclerosis Complex, and other tumor- or cortical malformation-associated epilepsies, and extending to more common, acquired epilepsies.

临床和治疗的影响作用是广泛的和不断扩大。通路活动异常,导致过度的细胞生长和增殖,已经有牵连的病理生理的许多人类癌症,包括零星的,孤立的肿瘤的特定器官和脏器,遗传性肿瘤综合征(盖尔丹和萨巴蒂尼,2007)。在许多情况下,特定的突变的一些组成部分的信号通路已被记录在案,造成过度活跃的靶蛋白或其下游效应。此外,失调因子也被牵连的其他一些疾病,包括代谢或环境的紊乱,如糖尿病,肥胖,心血管疾病,神经退行性疾病(曾等人。,2007)。从翻译的角度来看,潜在的作用,在病理生理学这些各种疾病有直接的治疗问题,因为一些临床使用的药物,抑制作用存在,包括原型,雷帕霉素。因此,雷帕霉素和其他抑制剂已测试在临床试验中的各种癌症和其他疾病(喜爱,2006;曾等人。,2007)。
总体而言,研究似乎充当主开关响应不同的生理
和病理刺激保持平衡的调节细胞生长,
扩散,和生存。中正日益被确认参与大
频谱的生理功能在正常条件和错调的一组不同的疾病。抑制剂,如雷帕霉素,正在考虑或已经在临床试验中的一些这些疾病。基于生理和病理生理特性的靶蛋白,它是合理的假设的研究
信号可能参与癫痫发病机制。在余下的这
审查,证据的作用,在癫痫和潜在的实用抑制剂作为反致痫剂将分析在不同类型的癫痫,开始与遗传性癫痫,结节性硬化症,与其他肿瘤或皮质畸形相关性癫痫,并延伸到更为常见,后天癫痫。追问

不够通顺啊 一看就是google翻译出来的 没诚意 能不能好好翻译下啊

温馨提示:答案为网友推荐,仅供参考
第1个回答  2011-11-17
临床和治疗的影响是全面且耐受继续扩大。异常活动耐受,导致细胞生长和增殖的过度,与许多人类癌症的病理生理机制,包括零星的,孤立的肿瘤,特定的器官与multiorgan、遗传肿瘤综合征(Guertin和Sabatini,2007)。在很多这样的情况下,特定的基因成分的信号传导通路耐受在案,导致其下游的hyperactivation耐受或对比。除了癌症、失调,也卷入了腐败丑闻耐受在许多其他疾病,包括代谢或环境紊乱,如糖尿病、肥胖、心血管疾病、神经退行性疾病(曾荫权等问题,2007)。从一个平面立场、潜在角色在病理生理学耐受各种障碍的治疗中有直接影响,像许多临床可抑制药物耐受存在,包括原型,雷帕霉素。因此,雷帕霉素和其他耐受抑制剂已经被经过临床试验各种癌症及其他疾病(Dancey,2006分;曾荫权等问题,2007)。

总的来说,似乎作为耐受总开关的不同的生理反应
和病理刺激维持内环境稳定,通过调节细胞生长,
增生和存活率。耐受日益被参与一个大
光谱的生理功能在正常条件下,在一个多元的集体特异表达基因疾病。耐受抑制剂,如雷帕霉素,正在考虑或已经在临床试验中许多这些疾病。基于生理和病理生理特性的耐受,可以合理假设耐受
信号可以epileptogenesis参与机制。 在剩馀的
审查证据的角色在epileptogenesis耐受和潜力的效用的inhibito耐受追问

能不能通顺点啊 直接google翻译不行呐

相关了解……

你可能感兴趣的内容

本站内容来自于网友发表,不代表本站立场,仅表示其个人看法,不对其真实性、正确性、有效性作任何的担保
相关事宜请发邮件给我们
© 非常风气网